

COVID-19 Boosters — Where from Here?

By [Dr. Paul A. Offit](#)

Theme: [Science and Medicine](#)

Global Research, May 02, 2022

[NEJM](#) 28 April 2022

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on [Instagram](#), [Twitter](#) and [Facebook](#). Feel free to repost and share widely Global Research articles.

On December 10, 2020, Pfizer presented results from a 36,000-person, two-dose, prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine, BNT162b2, to the Food and Drug Administration (FDA).¹ The vaccine was 95% effective at preventing severe illness in all age groups, independent of coexisting conditions or racial or ethnic background. A remarkable result. Six months later, studies showed that protection against severe disease was holding up.² The results of these epidemiologic studies were consistent with those of immunologic studies showing long-lived, high frequencies of Covid-19-specific memory B and T cells, which mediate protection against severe disease.³

In September 2021, 10 months after the BNT162b2 vaccine had become available, Israeli researchers found that protection against severe illness in people 60 years of age or older was enhanced by a third dose.⁴ In response, the Centers for Disease Control and Prevention (CDC) recommended that people 65 years of age or older should receive three doses of an mRNA vaccine.

In a study now reported in the *Journal*⁵ Israeli researchers found that in a study population with a median age of 72 years, protection against severe disease was further enhanced by a fourth dose of mRNA vaccine during the wave of infections caused by the B.1.1.529 (omicron) variant of SARS-CoV-2. These findings were considered by the FDA and CDC in their decision-making process regarding the use of an additional booster dose of mRNA vaccine for people 50 years of age or older.

What about booster dosing for persons who are younger? One year after the BNT162b2 vaccine became available, studies in the United States showed that a third dose of vaccine also enhanced protection against severe disease for people as young as 18 years of age.^{6,7} Unfortunately, these studies did not stratify patients according to whether they had coexisting conditions. Therefore, it was unclear who among these younger age groups most benefited from an additional dose. Nonetheless, the CDC later recommended that everyone

12 years of age or older should receive three doses of BNT162b2, regardless of whether risk factors were present. This universal booster recommendation led some summer camps, high schools, universities, hospitals, and businesses to require three doses of mRNA vaccine. In February 2022, in a study that did not support the booster recommendation for children, CDC researchers found that two doses of BNT162b2 induced long-lived protection against serious illness in children 12 to 18 years of age.⁸

In addition to protection against severe disease, the initial phase 3 trial of BNT162b2 — which was performed over a period of several months — also showed 95% protection against mild illness.¹ Unlike protection against severe illness, however, protection against mild illness, which is mediated by high titers of virus-specific neutralizing antibodies at the time of exposure, declined after 6 months, as would have been expected.² In response, studies by Pfizer were published in which a booster dose was shown to restore protection against mild illness⁹; unfortunately, this protection did not persist for more than a few months.⁶ Short-lived protection against mild illness will limit the ability of booster dosing to lessen transmission.

People are now confused about what it means to be fully vaccinated. It is easy to understand how this could happen. Arguably, the most disappointing error surrounding the use of Covid-19 vaccines was the labeling of mild illnesses or asymptomatic infections after vaccination as “breakthroughs.” As is true for all mucosal vaccines, the goal is to protect against serious illness — to keep people out of the hospital, intensive care unit, and morgue. The term “breakthrough,” which implies failure, created unrealistic expectations and led to the adoption of a zero-tolerance strategy for this virus. If we are to move from pandemic to endemic, at some point we are going to have to accept that vaccination or natural infection or a combination of the two will not offer long-term protection against mild illness.

In addition, because boosters are not risk-free, we need to clarify which groups most benefit. For example, boys and men between 16 and 29 years of age are at increased risk for myocarditis caused by mRNA vaccines.¹⁰ And all age groups are at risk for the theoretical problem of an “original antigenic sin” — a decreased ability to respond to a new immunogen because the immune system has locked onto the original immunogen. An example of this phenomenon can be found in a study of nonhuman primates showing that boosting with an omicron-specific variant did not result in higher titers of omicron-specific neutralizing antibodies than did boosting with the ancestral strain.¹¹ This potential problem could limit our ability to respond to a new variant.

It is now incumbent on the CDC to determine who most benefits from booster dosing and to educate the public about the limits of mucosal vaccines. Otherwise, a zero-tolerance strategy for mild or asymptomatic infection, which can be implemented only with frequent booster doses, will continue to mislead the public about what Covid-19 vaccines can and cannot do.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

Dr. Paul A. Offit, Children's Hospital of Philadelphia, Philadelphia.

Notes

1. Food and Drug Administration. Vaccines and related biological products advisory committee meeting. December 10, 2020 (<https://www.fda.gov/media/144245/download>, opens in new tab). [Google Scholar](#)

2. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021;398:1407–1416.

[Crossref](#), opens in new tab, [Web of Science](#), opens in new tab, [Medline](#), opens in new tab, [Google Scholar](#)

3. Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. *Science* 2021;374:abm0829–abm0829.

[Crossref](#), opens in new tab, [Web of Science](#), opens in new tab, [Medline](#), opens in new tab, [Google Scholar](#)

4. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. *N Engl J Med* 2021;385:1393–1400.

[Free Full Text](#), [Web of Science](#), opens in new tab, [Medline](#), opens in new tab, [Google Scholar](#)

5. Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. *N Engl J Med* 2022;386:1603–1614.

[Full Text](#), [Google Scholar](#)

6. Ferdinands JM, Rao S, Dixon BE, et al. Waning of 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 states, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:255–263.

[Web of Science](#), opens in new tab, [Medline](#), opens in new tab, [Google Scholar](#)

7. Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence — 25 U.S. jurisdictions, April 4–December 25, 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:132–138.

[Crossref](#), opens in new tab, [Medline](#), opens in new tab, [Google Scholar](#)

8. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. *N Engl J Med* 2022;386:713–723.

[Free Full Text](#), [Web of Science](#), opens in new tab, [Medline](#), opens in new tab, [Google Scholar](#)

9. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA* 2022;327:639–651.

[Crossref. opens in new tab](#), [Web of Science. opens in new tab](#), [Medline. opens in new tab](#), [Google Scholar](#)

10. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 2021;385:2132–2139.

[Free Full Text](#), [Web of Science. opens in new tab](#), [Medline. opens in new tab](#), [Google Scholar](#)

11. Gagne M, Moliva JI, Foulds KE, et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies, and protection against Omicron. February 4, 2022 (<https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1>. [opens in new tab](#)). preprint. [Google Scholar](#)

Featured image is from Children's Health Defense

The original source of this article is [NEJM](#)
Copyright © [Dr. Paul A. Offit](#), [NEJM](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Paul A. Offit](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca